Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: Retrospective multi-center investigation

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Tang, Shenjie ^a,b   Tan, Shouyong ^c   Yao, Lan ^b   Li, Fujian ^d   Li, Li ^e   Guo, Xinzhi ^f   Liu, Yidian ^b   Hao, Xiaohui ^b   Li, Yanqiong ^c   Ding, Xiuxiu ^c   Zhang, Zhanjun ^b   Tong, Li ^c   Huang, Jianan ^a  

^a SOOCHOW UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c GUANGZHOU CHEST HOSPITAL   (China)

^d Hangzhou Red Cross Hospital   (China)

^e TIANJIN HAIHE HOSPITAL   (China)

^f Henan Provincial Hospital of Infectious diseases   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ADVERSE OUTCOME; ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BODY MASS; CHINA; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG RESISTANT TUBERCULOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEALTH SURVEY; HUMAN; LUNG CAVITATION; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MULTICENTER STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SPUTUM SMEAR; TREATMENT FAILURE; ADOLESCENT; AGED; CLINICAL TRIAL; EPIDEMIOLOGY; MICROBIOLOGY; MORTALITY; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHINA; HUMANS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84891960518     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082943     Document Type: Article

References (40)

1. WHO (2012) Global tuberculosis report 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO.
2. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet, 375: 1830-1843. doi:10.1016/S0140- 6736(10)60410-2. PubMed: 20488523.
3. World Health Organization (2010) Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO.
4. Zhao YL, Xu SF, Wang LX, Chin DP, Wang SF et al. (2012) National Survey of Drug-Resistant Tuberculosis in China. N Engl J Med, 366: 2161-2170. doi:10.1056/NEJMoa1108789. PubMed: 22670902.
5. National Technical Steering Group of the Epidemiological Sampling Survey for Tuberculosis, Implementing Office of the Epidemiological Sampling Survey for Tuberculosis (2012) The prevalence of pulmonary tuberculosis in a national survey across China in 2010. Zhonghua Jie He He Hu Xi Za Zhi, 35(9): 665-658.
6. Li X, Wang H, Jing H, Wang Y, Yu C et al. (2012) Population-based surveillance of extensively drug-resistant tuberculosis in Shandong Province, China. Int J Tuberc Lung Dis, 16(5): 612-614. PubMed: 22410186.
7. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB (2010) Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis. Clin Infect Dis, 51(1): 6-14. doi:10.1086/653115. PubMed: 20504231.
8. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H et al. (2008) Treatment Outcomes for HIV-Uninfected Patients with Multidrug-Resistant and Extensively Drug-Resistant. Tuberculosis - Clin Infect Dis, 47: 496-502. doi:10.1086/590005.
9. Vashakidze L, Salakaia A, Shubladze N, Cynamon M, Barbakadze K et al. (2009) Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia. Int J Tuberc Lung Dis, 13: 1148-1153. PubMed: 19723406.
10. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS et al. (2008) Treatment outcomes and long-term survival in patients with extensively drugresistant tuberculosis. Am J Respir Crit Care Med, 178: 1075-1082. doi: 10.1164/rccm.200801-132OC. PubMed: 18703792.
11. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG et al. (2007) Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis, 45: 1290-1295. doi:10.1086/522537. PubMed: 17968823.
12. WHO (2009) Guidelines for surveillance of drug resistance in tuberculosis (fourth edition) WHO/HTM/TB.2009.422. Geneva, Switzerland: WHO.
13. World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO.
14. World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. WHO/HTM/TB/2011.6. Geneva: WHO.
15. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD et al. (2005) Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis, 9: 640-645. PubMed: 15971391. (Pubitemid 40826156)
16. Deng Y, Wang Y, Wang J, Jing H, Yu C et al. (2011) Laboratory-based surveillance of extensively drug-resistant tuberculosis, China. Emerg Infect Dis, 17: 495-497. doi:10.3201/eid1703.100812. PubMed: 21392442.
17. Zhao M, Li X, Xu P, Shen X, Gui X et al. (2009) Transmission of MDR and XDR tuberculosis in Shanghai, China. PLOS ONE, 4: e4370. doi: 10.1371/journal.pone.0004370. PubMed: 19190774.
18. Qi YC, Ma MJ, Li DJ, Chen MJ, Lu QB et al. (2012) Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Multi-Ethnic Region, Xinjiang Uygur Autonomous Region, China. PLOS ONE, 7(2): e32103. doi:10.1371/journal.pone. 0032103. PubMed: 22384153.
19. Shi D, Li H, Zhao Y, Jia Q, Coulter C et al. (2012) Extensively drugresistant tuberculosis, central china, 2007-2009. Emerg Infect Dis, 18(11): 1904-1905. doi:10.3201/eid1811.120046. PubMed: 23092762.
20. Lai CC, Tan CK, Huang YT, Chou CH, Hung CC et al. (2008) Extensively drug-resistant mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a medical center in Taiwan. Clin Infect Dis, 47: e57-e63. doi:10.1086/591702. PubMed: 18715157.
21. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC et al. (2008) Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis, 46: 42-49. doi:10.1086/524017. PubMed: 18171212. (Pubitemid 351263558)
22. Myneedu VP, Visalakshi P, Verma AK, Behera D, Bhalla M (2011) Prevalence of XDR TB cases-a retrospective study from a tertiary care TB hospital. Indian J Tuberc, 58(2): 54-59. PubMed: 21644390.
23. Moodley P, Shah NS, Tayob N, Connolly C, Zetola N et al. (2011) Spread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa. PLOS ONE, 6(5): e17513. doi:10.1371/journal.pone.0017513. PubMed: 21655324.
24. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet, 368: 1575-1580. doi:10.1016/S0140-6736(06)69573-1. PubMed: 17084757. (Pubitemid 44780738)
25. Koenig R (2008) Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science, 319: 894-897. doi: 10.1126/science.319. 5865.894. PubMed: 18276863. (Pubitemid 351263739)
26. O'Donnell MR, Zelnick J, Werner L, Master I, Loveday M et al. (2011) Extensively drug-resistant tuberculosis in women, KwaZulu-Natal, South Africa. Emerg Infect Dis, 17(10): 1942-1945. doi:10.3201/eid1710.110105. PubMed: 22000378.
27. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S et al. (2010) Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J, 36(3): 584-593. doi: 10.1183/09031936.00003710. PubMed: 20185428.
28. Yu MC, Wu MH, Jou R (2008) Extensively drug-resistant tuberculosis, Taiwan. Emerg Infect Dis, 14: 849-850. doi:10.3201/eid1405.071398. PubMed: 18439381.
29. Tabarsi P, Chitsaz E, Baghaei P, Shamaei M, Farnia P et al. (2010) Impact of Extensively Drug-Resistant Tuberculosis on Treatment Outcome of Multidrug-Resistant Tuberculosis Patients with Standardized Regimen: Report from Iran. Microb Drug Resist, 16(1): 81-86. doi:10.1089/mdr.2009.0073. PubMed: 20192820.
30. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ et al. (2007) Trend of antituberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis, 11: 571-576. PubMed: 17439684.
31. Liu CH, Li L, Chen Z, Wang Q, Hu YL et al. (2011) Characteristics and Treatment Outcomes of Patients with MDR and XDR Tuberculosis in a TB Referral Hospital in Beijing: A 13-Year Experience. PLOS ONE, 6(4): e19399. doi:10.1371/journal.pone.0019399. PubMed: 21559362.
32. Kliiman K, Altraja A (2009) Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J, 33: 1085-1094. doi:10.1183/09031936.00155708. PubMed: 19164345.
33. Dheda K, Shean K, Zumla A, Badri M, Streicher EM et al. (2010) Early treatment outcomes and HIV status of patients with extensively drugresistant tuberculosis in South Africa: a retrospective cohort study. Lancet, 375: 1798-1807. doi:10.1016/S0140-6736(10)60492-8. PubMed: 20488525.
34. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C et al. (2007) Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis, 13: 780-782. doi:10.3201/eid1305.070200. PubMed: 18044040. (Pubitemid 46698749)
35. Faustini A, Hall AJ, Perucci CA (2006) Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax, 61: 158-163. doi:10.1136/thx.2005.045963. PubMed: 16254056. (Pubitemid 43235434)
36. Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK et al. (2008) Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet, 372: 1403-1409. doi: 10.1016/S0140-6736(08) 61204-0. PubMed: 18723218.
37. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM (2009) Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLOS ONE 4: e6914. doi:10.1371/journal.pone.0006914. PubMed: 19742330.
38. Lee J, Lee CH, Kim DK, Yoon HI, Kim JY et al. (2011) Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes. Korean J Intern Med, 26: 153-159. doi:10.3904/kjim.2011.26. 2.153. PubMed: 21716591.
39. Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A et al. (2010) Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model. Antimicrob Agents Chemother, 54(11): 4765-4771. doi:10.1128/AAC.00968-10. PubMed: 20805388.
40. Caminero JA, Sotgiu G, Zumla A, Migliori GB (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis, 10: 621-629. PubMed: 20797644.